Rishav Aggarwal

Dr. Rishav Aggarwal

University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Closed access
TYTaehwan Yoo
Taehwan Yoo
RARishav Aggarwal
Rishav Aggarwal
TWTzu-Fei Wang
Tzu-Fei Wang
BSBhagwan Satiani
Bhagwan Satiani
MHMounir J. Haurani
Mounir J. Haurani

31 October 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
RARishav Aggarwal
Rishav Aggarwal
KPKoray Niels Potel
Koray Niels Potel
EMedward mcfalls
edward mcfalls
Tammy A ButterickTammy A Butterick
Tammy A Butterick
RKRosemary F. Kelly
Rosemary F. Kelly
Ischemic heart disease affects millions of people around the world. Current treatment options, including coronary artery bypass grafting, do not result in full functional recovery, highlighting the need for novel adjunctive therapeutic approaches. Hibernation describes the myocardial response to prolonged ischemia and involves a set of complex cytoprotective metabolic and functional adaptations. PGC1-alpha, a key regulator of mitochondrial energy metabolism and inhibitor of oxidant-stress-inflammatory signaling, is known to be downregulated in hibernating myocardium. PGC1-alpha is a critical component of cellular stress responses and links cellular metabolism with inflammation in the ischemic heart. While beneficial in the acute setting, a chronic state of hibernation can be associated with self-perpetuating oxidant stress-inflammatory signaling which leads to tissue injury. It is likely that incomplete functional recovery following revascularization of chronically ischemic myocardium is due to persistence of metabolic changes as well as prooxidant and proinflammatory signaling. Enhancement of PGC1-alpha signaling has been proposed as a possible way to improve functional recovery in patients with ischemic heart disease. Adjunctive mesenchymal stem cell therapy has been shown to induce PGC1-alpha signaling in hibernating myocardium and could help improve clinical outcomes for patients undergoing bypass surgery.

1 April 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
CHChelsea R. Horwood
Chelsea R. Horwood
DMDaniel Mansour
Daniel Mansour
MAMahmoud Abdel-Rasoul
Mahmoud Abdel-Rasoul
GMGregory Metzger
Gregory Metzger
JHJing Han
Jing Han
SMSusan Moffatt-Bruce
Susan Moffatt-Bruce

Verified
Journal Article
Open access
PDF file
RARishav Aggarwal
Rishav Aggarwal
KPKoray Niels Potel
Koray Niels Potel
ASAnnie Shao
Annie Shao
SSSimon Wai Man So
Simon Wai Man So
CSCory Swingen
Cory Swingen
RKRosemary F. Kelly
Rosemary F. Kelly
Diastolic dysfunction persists despite coronary artery bypass graft surgery (CABG) in patients with hibernating myocardium (HIB). We studied whether the adjunctive use of a mesenchymal stem cells (MSCs) patch during CABG improves diastolic function by reducing inflammation and fibrosis. HIB was induced in juvenile swine by placing a constrictor on the left anterior descending (LAD) artery, causing myocardial ischemia without infarction. At 12 weeks, CABG was performed using the left-internal-mammary-artery (LIMA)-to-LAD graft with or without placement of an epicardial vicryl patch embedded with MSCs, followed by four weeks of recovery. The animals underwent cardiac magnetic resonance imaging (MRI) prior to sacrifice, and tissue from septal and LAD regions were collected to assess for fibrosis and analyze mitochondrial and nuclear isolates. During low-dose dobutamine infusion, diastolic function was significantly reduced in HIB compared to the control, with significant improvement after CABG + MSC treatment. In HIB, we observed increased inflammation and fibrosis without transmural scarring, along with decreased peroxisome proliferator-activated receptor-gamma coactivator (PGC1α), which could be a possible mechanism underlying diastolic dysfunction. Improvement in PGC1α and diastolic function was noted with revascularization and MSCs, along with decreased inflammatory signaling and fibrosis. These findings suggest that adjuvant cell-based therapy during CABG may recover diastolic function by reducing oxidant stress–inflammatory signaling and myofibroblast presence in the myocardial tissue.

1 January 2022 in Seminars in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
RARishav Aggarwal
Rishav Aggarwal
SJScott Jackson
Scott Jackson
NLNicholas T. Lemke
Nicholas T. Lemke
SSSara J. Shumway
Sara J. Shumway
RKRose F. Kelly
Rose F. Kelly
SHStephen J. Huddleston
Stephen J. Huddleston

1 May 2019 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Closed access
TYTaehwan Yoo
Taehwan Yoo
RARishav Aggarwal
Rishav Aggarwal
SBShayna Brathwaite
Shayna Brathwaite
BSBhagwan Satiani
Bhagwan Satiani
MHMounir J. Haurani
Mounir J. Haurani